Navigation Links
Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
Date:12/18/2009

CARY, N.C., Dec. 18 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it will host a conference call at 8:30 AM ET on Thursday, January 7, 2010, to discuss its financial guidance for 2010. Cornerstone intends to issue a press release outlining its financial guidance for 2010 prior to the conference call.

To participate in the live conference call, please dial 866-271-5140 (U.S. callers) or 617-213-8893 (international callers), and provide passcode 45969044. A live webcast of the call will also be available through the Investor Relations section of the Company's website. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on January 7, 2010, by dialing 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), and providing passcode 88256043.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force, which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 26, 2009 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.

SOURCE Cornerstone Therapeutics Inc.


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
2. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Jan. 16, 2017  Rigel Pharmaceuticals (Nasdaq: ... and January 16, 2017 the Compensation Committee of Rigel,s ... options to purchase an aggregate of 214,000 shares of ... granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, ... employees entering into employment with Rigel, in accordance with ...
(Date:1/15/2017)... 14, 2017 ImmersiveTouch Inc., the global leader ... announced recent appointments strengthening their Executive Management team.  ... as Chief Executive Officer, Jay Banerjee as ... President of Sales and Jia Luo , PhD ... Mr. Bowman has 20 years experience commercializing ...
(Date:1/13/2017)... 13, 2017 Constant research ongoing in ... collectively contribute to the demand for western blotting technique. The ... of US$ 551.0 Mn by 2016 end. Developing economies in ... lucrative markets for western blotting, whereas North America ... ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... organized to provide first-quality education and high-level training standards to an international multidisciplinary ... of eating disorder problems. As a way to further its mission at the ...
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s ... the field of midmarket financial software. , Members of the VAR Stars were selected ... based on revenue and those firms chosen represent a wide range of size and ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... has achieved accreditation for its specialty care services. Albertsons Companies is the ... specialty care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ ...
(Date:1/15/2017)... ... , ... The Gravity Vault Indoor Rock Climbing Gym is excited to announce ... the 14,000+ square foot climbing gym, the owners anticipate to open sometime in February ... and two in New York. With this being its first location in Pennsylvania, The ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products and ... Emoji Scale is now available on Apple as a fun, free emoji sticker pack ... choosing one of the ten color coded values on The Emoji Scale. , ...
Breaking Medicine News(10 mins):